DFX Intelligence
Borrowers
93 borrower groups currently held, grade A and BWhat a borrower group isA borrower group is every spelling of one credit agreement's borrower across the BDCs that hold it (Icefall Parent, Icefall Topco and Icefall Bidco are one). Grade A and B groups are listed; a short one-word stem (grade C) is kept apart and never merged across filers. Principal is the sum of BDC pieces and is a lower bound.Principal and marks are the filers' figures at each BDC's latest quarter end, summed. Maturity is the filer's tagged date or the date written into the identifier; a BDC that tags neither leaves it unstated.
Industry as filed contains “Healthcare & Pharmaceuticals” (remove)
Start from
93 borrower groups
| Borrower | Sponsor | BDCs | Principal held | On cost | Spread | Next maturity | First seen |
|---|---|---|---|---|---|---|---|
| Allied Benefit Systems Intermediate LLC Life sciences | unattributed | 13 | at least $297M | 100c | 1 pts | Oct 1, 2030 | Dec 31, 2022 |
| OB Hospitalist Group, Inc Life sciences | Sponsor not establishedpossible: Kohlberg & Company (a company of this name is on the sponsor's portfolio page) | 16 | at least $277M | 101c | 1 pts | Jan 1, 2031 | Dec 31, 2021 |
| TecoStar Holdings, Inc Life sciences | unattributed | 7 | at least $258M | 101c | 1 pts | May 12, 2032 | Dec 31, 2021 |
| A•• V••••• Life sciences | Sponsor not establishedpossible: R•••• C•••••• G••••• L•• (a company of this name is on the sponsor's portfolio page) | 2 | at least $100M | 100c | n/a | Mar 27, 2027 | Jun 30, 2024 |
| Z•••• C••• M••••••••• B••••• I•• Life sciences | unattributed | 9 | at least $86.4M | 98c | 0 pts | Sep 1, 2029 | Dec 31, 2022 |
| S•••••• L•••• I••••••••• L•• Life sciences | unattributed | 9 | at least $83.7M | 75c | 0 pts | Jul 1, 2031 | Dec 31, 2023 |
| E•••••• L•• Life sciences | unattributed | 7 | at least $71.3M | 97c | 0 pts | Sep 14, 2030 | Dec 31, 2021 |
| B••••• H••••• H•••••••• L•• Life sciences | Sponsor not establishedpossible: A•••••••• I••••••••• M••••••••• L•• (a company of this name is on the sponsor's portfolio page) | 6 | at least $64.8M | 100c | 0 pts | May 1, 2028 | Mar 31, 2024 |
| B••• B•••••• P••••••••• I•• Life sciences | unattributed | 4 | at least $61.6M | 100c | 1 pts | Jan 16, 2033 | Dec 31, 2025 |
| S•• E•• C••• H•••••• L•• Life sciences | Sponsor not establishedpossible: M••••••• C•••••• L•• (a company of this name is on the sponsor's portfolio page) | 10 | at least $59.8M | 100c | 1 pts | Oct 5, 2029 | Dec 31, 2022 |
| M•••• P••••••••• I•• Life sciences | Sponsor not establishedpossible: C••••••••• C•••••• P•••••••• L•• (Form D signer consensus, grade B) | 7 | at least $59.5M | 100c | 0 pts | Oct 1, 2031 | Dec 31, 2021 |
| C••••••• B••••• I•• Life sciences | Sponsor not establishedpossible: C•••• S••••• C•••••• (a company of this name is on the sponsor's portfolio page) | 13 | at least $52.5M | 100c | 0 pts | May 8, 2033 | Dec 31, 2022 |
| T•••••• B••••• H••••••• L•• Life sciences | unattributed | 9 | at least $49.3M | 86c | 23 pts | May 1, 2028 | Dec 31, 2021 |
| C•• H••••••••• P••••••••• I•• Life sciences | M••••• E••••• P•••••••• L•• inferred | 6 | at least $45.7M | 100c | 0 pts | Sep 17, 2031 | Sep 30, 2021 |
| W•••••• T••••••••• I•• Life sciences | unattributed | 11 | at least $45.6M | 100c | 0 pts | Oct 1, 2029 | Dec 31, 2021 |
| A•• H••••• Life sciences | unattributed | 5 | at least $42.6M | 98c | n/a | Aug 1, 2032 | Dec 31, 2024 |
| A••••• A•••••••• I•• Life sciences | unattributed | 4 | at least $38.7M | 100c | 0 pts | Dec 31, 2031 | Sep 30, 2022 |
| A••••• I••••••••• Life sciences | unattributed | 2 | at least $37.9M | 99c | 0 pts | Jun 1, 2028 | Sep 30, 2022 |
| B•••••••• S•••• Life sciences | unattributed | 2 | at least $34.7M | 106c | 1 pts | Feb 26, 2032 | Mar 31, 2025 |
| H•••••• I••••••••• L•• Life sciences | unattributed | 3 | at least $31.6M | 101c | 0 pts | Nov 15, 2028 | Dec 31, 2021 |
| B•••••• O•••• L•• Life sciences | unattributed | 1 | at least $25.9M | 100c | n/a | May 31, 2027 | Jun 30, 2023 |
| P••••••••• H••••• H•••••••• I•• Life sciences | unattributed | 9 | at least $25.3M | 99c | 1 pts | Mar 19, 2032 | Dec 31, 2021 |
| H••••••••• Life sciences | unattributed | 1 | at least $24.7M | 100c | n/a | Apr 10, 2034 | Jun 30, 2026 |
| U••• H••••• L•• Life sciences | unattributed | 2 | at least $23.8M | 99c | 1 pts | May 26, 2031 | Jun 30, 2025 |
| R•• H•••••••• I•• Life sciences | unattributed | 10 | at least $20.0M | 102c | 0 pts | Dec 23, 2030 | Dec 31, 2021 |
| E•• H••••• Life sciences | unattributed | 2 | at least $18.9M | 100c | 0 pts | Aug 7, 2030 | Sep 30, 2024 |
| H••••• B•••• G•••••• G••• Life sciences | unattributed | 2 | at least $16.9M | 98c | 0 pts | Apr 29, 2033 | Jun 30, 2026 |
| V••••• B•••• L•••••• Life sciences | unattributed | 2 | at least $14.5M | 99c | 0 pts | Aug 20, 2030 | Sep 30, 2025 |
| B•••• S•••• Life sciences | unattributed | 3 | at least $14.4M | 103c | 6 pts | Jun 30, 2031 | Sep 30, 2024 |
| S••••• O•••• Life sciences | Sponsor not establishedpossible: I••••••• C•••••• P•••••••• L•• (a company of this name is on the sponsor's portfolio page) | 2 | at least $14.3M | 101c | 0 pts | Jul 31, 2028 | Dec 31, 2024 |
| E•••• B••••• L•• Life sciences | unattributed | 2 | at least $14.1M | 99c | 0 pts | Mar 12, 2033 | Mar 31, 2026 |
| N•••• B•••• Life sciences | unattributed | 2 | at least $13.3M | 99c | 0 pts | Jun 24, 2032 | Jun 30, 2025 |
| W••• C••••••••• B••••• L•• Life sciences | unattributed | 2 | at least $13.0M | 100c | 0 pts | Dec 20, 2032 | Dec 31, 2025 |
| B••••• S••••••••• L••••• Life sciences | unattributed | 2 | at least $11.9M | 101c | n/a | Mar 25, 2028 | Jun 30, 2024 |
| P•••••••• C•••••••• Life sciences | unattributed | 3 | at least $10.9M | 95c | n/a | Apr 16, 2032 | Sep 30, 2025 |
| G•••• E••••••••• D••••• C••••• P• Life sciences | unattributed | 1 | at least $10.0M | 85c | n/a | Sep 30, 2026 | Dec 31, 2021 |
| A••••• I••••••••• L•• Life sciences | unattributed | 2 | at least $9.9M | 102c | 0 pts | Jun 5, 2031 | Jun 30, 2025 |
| P••••••••• M•••••• C••• L•• Life sciences | unattributed | 2 | at least $9.5M | 100c | n/a | Jul 1, 2032 | Sep 30, 2025 |
| A••••••• C••• A••••••• H••••• L•• Life sciences | unattributed | 2 | at least $9.1M | 101c | n/a | Aug 20, 2030 | Sep 30, 2025 |
| R•• N•••••• Life sciences | unattributed | 2 | at least $9.0M | 100c | n/a | Oct 17, 2031 | Dec 31, 2024 |
| A•• I••••••• Life sciences | R••••••••• C•••••• P••••••• inferred | 2 | at least $8.6M | 101c | n/a | Mar 19, 2032 | Mar 31, 2025 |
| O•••••• Life sciences | unattributed | 5 | at least $7.6M | 101c | n/a | Nov 21, 2030 | Dec 31, 2021 |
| R••••• O••••••••• Life sciences | unattributed | 2 | at least $7.5M | 101c | n/a | Feb 28, 2031 | Mar 31, 2025 |
| E••••••• P••••••• Life sciences | Sponsor not establishedpossible: M••••••• C•••••• L•• (a company of this name is on the sponsor's portfolio page) | 2 | at least $6.6M | 101c | n/a | Oct 5, 2029 | Dec 31, 2023 |
| A••••••••• Life sciences | unattributed | 4 | at least $6.4M | 94c | n/a | Jun 20, 2028 | Dec 31, 2021 |
| E••• S••••••• G•••• Life sciences | unattributed | 3 | at least $5.8M | 98c | n/a | Jun 28, 2029 | Dec 31, 2022 |
| A•••••• H•••••• G••• Life sciences | unattributed | 2 | at least $5.8M | 99c | n/a | Nov 29, 2032 | Dec 31, 2025 |
| D••••• I•• Life sciences | unattributed | 3 | at least $5.5M | 100c | n/a | May 9, 2031 | Jun 30, 2024 |
| R••••••••• Life sciences | unattributed | 5 | at least $5.5M | 102c | n/a | Dec 19, 2030 | Dec 31, 2022 |
| S••••• B••••••••• H••••••••• L•• Life sciences | unattributed | 6 | at least $5.0M | 74c | n/a | Dec 31, 2029 | Sep 30, 2021 |
Page 1 of 2Next
The borrower, lender and sponsor names past the first 3 rows are hidden. Open a row to reveal that record with a free account (5 a month), or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source is public either way.